Cargando…

Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial

BACKGROUND: In the cetuximab after progression in KRAS wild-type colorectal cancer patients (CAPRI) trial patients with metastatic colorectal cancer (mCRC) received 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) and cetuximab in first line followed by 5-Fluorouracil, folinic acid, oxaliplatin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martinelli, E, Cardone, C, Troiani, T, Normanno, N, Pisconti, S, Sforza, V, Bordonaro, A R, Rachiglio, A M, Lambiase, M, Latiano, T P, Modoni, G, Cordio, S, Giuliani, F, Biglietto, M, Montesarchio, V, Barone, C, Tonini, G, Cinieri, S, Febbraro, A, Rizzi, D, De Vita, F, Orditura, M, Colucci, G, Maiello, E, Ciardiello, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2017
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5548975/ https://www.ncbi.nlm.nih.gov/pubmed/28848656 http://dx.doi.org/10.1136/esmoopen-2016-000086

Ejemplares similares

Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial
por: Martini, Giulia, et al.
Publicado: (2023)

Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM)
por: Ciardiello, D., et al.
Publicado: (2022)

Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer
por: Cardone, Claudia, et al.
Publicado: (2019)

Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment
por: Martinelli, Erika, et al.
Publicado: (2017)

Genomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents
por: Rachiglio, Anna Maria, et al.
Publicado: (2019)

Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM)
por: Orlando, Laura, et al.
Publicado: (2020)

Comment on ‘A comparison of three methods for detecting KRAS mutations in formalin-fixed colorectal cancer specimens’
por: Normanno, N, et al.
Publicado: (2012)

Cetuximab as third‐line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild‐type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials
por: Martini, G., et al.
Publicado: (2023)

Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case
por: Martinelli, Erika, et al.
Publicado: (2018)

Detectors: Calorimeters at Capri
Publicado: (1991)

Getting heavy on Capri
Publicado: (2008)

First clinical implementation of the Capri applicator
por: Gloi, Aime M.
Publicado: (2014)

Skin Toxicity as Predictor of Survival in Refractory Patients with RAS Wild-Type Metastatic Colorectal Cancer Treated with Cetuximab and Avelumab (CAVE) as Rechallenge Strategy
por: Ciardiello, Davide, et al.
Publicado: (2021)

Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
por: Macarulla, T, et al.
Publicado: (2015)

Détecteurs : Calorimètres à Capri
Publicado: (1991)

Capri Symposia 1983 - 1987
por: Buccella, Franco
Publicado: (1990)

Rosetta in CAPRI rounds 13–19
por: Fleishman, Sarel J, et al.
Publicado: (2010)

CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients
por: Napolitano, Stefania, et al.
Publicado: (2022)

Capri Symposium : Symmetry in Fundamental Interactions
Publicado: (1987)

Dynamics of RAS/BRAF Mutations in cfDNA from Metastatic Colorectal Carcinoma Patients Treated with Polychemotherapy and Anti-EGFR Monoclonal Antibodies
por: Rachiglio, Anna Maria, et al.
Publicado: (2022)

Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study)
por: Giommoni, Elisa, et al.
Publicado: (2021)

Sense and simplicity in HADDOCK scoring: Lessons from CASP‐CAPRI round 1
por: Vangone, A., et al.
Publicado: (2016)

CAPRI enables comparison of evolutionarily conserved RNA interacting regions
por: Panhale, Amol, et al.
Publicado: (2019)

Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
por: Ciardiello, F, et al.
Publicado: (2006)

9th Capri Symposium on Elementary-particle Physics
Publicado: (1991)

Antitumor Activity of Sorafenib in Human Cancer Cell Lines with Acquired Resistance to EGFR and VEGFR Tyrosine Kinase Inhibitors
por: Morgillo, Floriana, et al.
Publicado: (2011)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941
por: Ciardiello, Davide, et al.
Publicado: (2022)

Reliability and Efficiency of the CAPRI-3 Metastatic Prostate Cancer Registry Driven by Artificial Intelligence
por: Bosch, Dianne, et al.
Publicado: (2023)

A Type III restriction–modification system in Mycoplasma mycoides subsp. capri
por: Algire, Mikkel A., et al.
Publicado: (2012)

Limits and potential of targeted sequencing analysis of liquid biopsy in patients with lung and colon carcinoma
por: Rachiglio, Anna Maria, et al.
Publicado: (2016)

Immunotherapy for Biliary Tract Cancer in the Era of Precision Medicine: Current Knowledge and Future Perspectives
por: Ciardiello, Davide, et al.
Publicado: (2022)

Mean overall survival gain with aflibercept plus FOLFIRI vs placebo plus FOLFIRI in patients with previously treated metastatic colorectal cancer
por: Joulain, F, et al.
Publicado: (2013)

CAPriCORN: Chicago Area Patient-Centered Outcomes Research Network
por: Kho, Abel N, et al.
Publicado: (2014)

4th Capri Symposium : Towards the Unification of all Interactions
Publicado: (1986)

IVF, from the past to the future: the inheritance of the Capri Workshop Group
Publicado: (2020)

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)
por: Guida, Michele, et al.
Publicado: (2018)

Erratum to: IVF, from the past to the future: the inheritance of the Capri Workshop Group
Publicado: (2020)

Variability in ‘Capri’ Everbearing Strawberry Quality during a Harvest Season
por: Simkova, Kristyna, et al.
Publicado: (2023)

Disease Control With FOLFIRI Plus Ziv-aflibercept (zFOLFIRI) Beyond FOLFIRI Plus Bevacizumab: Case Series in Metastatic Colorectal Cancer (mCRC)
por: El-Deiry, Wafik S., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_la062f3t2e6p455u6tebbl0cod